Division of Roche
Latest From Trophos SA
Appointments: Eli Lilly, Alexion, Actelion, Polyphor, Constellation, Bone Therapeutics and Allied Minds
This week's roundup includes the announced retirement of Lilly's CFO, high-level appointments by Alexion Pharmaceuticals, Actelion and Constellation, and board elections by Wilson Therapeutics, Bone Therapeutics and Atlantic Healthcare.
Initial VC and institutional funding from a French syndicate will support further drug development at Paris-based Horama, which aims to put two targeted gene therapies for hereditary retinitis pigmentosa in the clinic by 2018.
In a deal worth over $1 billion, Depomed got US rights to Janssen's pain drug Nucynta; Roche bought the majority stake in Foundation Medicine. FOPOs drove a large part of biopharma financing.
In an interview at the J.P. Morgan meeting, Roche R&D and partnering execs John Reed and Sophie Kornowski-Bonnet review progress and aspirations in new therapeutic areas like ophthalmology, antimicrobials and CNS diseases.
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Senior Management
Christine Placet, CEO
Marceline Clementine, CFO
Rebecca Pruss, PhD, CSO
- Contact Info
Phone: (33) (0)491 828 282
Parc scientifique de Luminy
Marseille Cedex 9, 13288
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.